TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06013397

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic diet (KD) is a high-fat, low-carbohydrate and moderate protein diet pattern, suitable for refractory epilepsy, glucose carrier protein 1 deficiency, pyruvate dehydrogenase deficiency, tumors and some genetic metabolic diseases. The ketogenic diet has been used to treat epilepsy for nearly 100 years, and its safety has been recognized by the medical community. In 2015, the ketogenic diet was included in the Clinical Diagnosis and Treatment Guidelines - Epilepsy Volume and became a commonly used treatment for refractory epilepsy.
Study: NCT05717179

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: At baseline and at weeks 12, 24 and 48, patients will undergo an ultrasound examination of 44 joints by one investigator, who is blinded to the strategic arm and all clinical data. The following joints will be assessed: bilateral wrists (distal radio-ulnar joint, radio-carpal, mid-carpal recesses), 1st - 5th MCP, 1st - 5th PIP, elbows, glenohumeral, acromioclavicular, sternoclavicular, knees, ankles and 1st - 5th MTP. At wrists, MCP and PIP joints, palmar and dorsal sites including synovial recess, extensor and flexor tendons will be investigated whereas at feet the dorsal site (plus the lateral aspects of MTP5) including synovial recess and extensor tendons will be evaluated. Further, we will assess the following: at elbows the dorsal and anterior recess, at shoulders the dorsal recess, at knees the suprapatellar as well as the medial and lateral femoro-tibial recess and at ankles the anterior, lateral and medial recess of the tibiotalar joint.
Study: NCT04898426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced bowel preparation instruction
Description: Automated delivery of SMS, pre-recorded phone call, and link to an information website.
Study: NCT06006858

Intervention type: BIOLOGICAL
Intervention: Moderna COVID-19 Vaccine
Description: Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
Study: NCT06553378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric Oncology Supportive Clinic
Description: Subjects in the intervention arm will be seen within four weeks of recruitment. Clinical assessment involves a Comprehensive Geriatric Assessment (CGA) and Supportive Care Assessment conducted by a geriatric-oncologist. Both clinical assessments and targeted interventions are supported by a multi-disciplinary team comprising the geriatrician, geriatric trained nurse, physiotherapist, occupational therapist, speech therapist, pharmacist, dietician, and medical social worker. We will conduct an initial GOSC assessment, with a follow up review during oncology treatment. Subsequently, further GOSC clinic sessions duration of follow up will be determined by the subject's underlying disease, symptom burden and clinical course during treatment.
Study: NCT06276608

Intervention type: DIAGNOSTIC_TEST
Intervention: Iron status
Description: Iron status will be based on preoperative ferritin levels: a ferritin \< 10 mcg/L will be considered as iron deficiency, ferritin levels \> 10 mcg/L will be considered normal
Study: NCT05465733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab;Pemetrexed
Description: single agent, 300mg Q3W IH until disease progressed,The duration of treatment with Envafolimab should not exceed 2 years.
Study: NCT05818800

Intervention type: DEVICE
Group type: OTHER
Intervention: digital solution
Description: randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions

Intervention type: DEVICE
Group type: OTHER
Intervention: digital solution
Description: randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: randomised controlled trial where patients with hypertension will be randomised r to standard care
Study: NCT06449755

Intervention type: OTHER
Group type: OTHER
Intervention: Quick DASH Questionnaire
Description: Quick DASH is an 11-question questionnaire that assesses upper extremity functionality.

Intervention type: OTHER
Group type: OTHER
Intervention: Quick DASH Questionnaire
Description: Quick DASH is an 11-question questionnaire that assesses upper extremity functionality.
Study: NCT05129982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: whole body vibration is a modality of physical therapy
Study: NCT06471543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RN0361
Description: solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN0361
Description: solution
Study: NCT05213741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autonomous navigation of a magnetic colonoscope
Description: The proposed magnetic-assisted colonoscope system consists of an megnetic field nevigator, magnetic-assisted colonoscope, and image receiving decoder. All participants will receive the magnetic-assisted colonoscopic examination by using this proposed magnetic-assisted colonoscope system
Study: NCT05073588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indo Mediterranean diet
Description: Mediterranean diet has been shown to be effective in NAFLD adult patients. In India, it is very difficult to follow Mediterranean diet, so one group will be given Indianized version of mediterranean diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calorie restricted diet
Description: One group will be given diet restricted in calories, which most of the patients follow to lose weight
Study: NCT06055751

Intervention type: DEVICE
Intervention: TAVR Procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473)
Description: No intervention will be done as part of this prospective registry. Implantation of Boston Scientific Loop Recorder (LUX-Dx) will be performed regardless of this research and outside this research protocol per standard of care
Study: NCT05944887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: administration of a bolus of lidocaine 1.5 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline administration as placebo
Description: administration of a bolus of saline solution as a placebo
Study: NCT05328076

Intervention type: DRUG
Intervention: Indocyanine green
Description: Indocyanine green is used to perform intraoperative angiography.

Intervention type: DEVICE
Intervention: SPY Portable Handheld Imaging (SPY-PHI)
Description: The device is used to perform intraoperative angiography.
Study: NCT05944887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol injection
Description: Sedation by total intravenous administration (TIVA) of propofol
Study: NCT03584295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal
Description: Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R to facilitate early extubation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Patient with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional Care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
Study: NCT05831059

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed radio frequency therapy
Description: Pulse Radio Frequency mode is a high voltage and low temperature Radio Frequency mode formed by discontinuous and pulsed current around nerve tissue

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed radio frequency therapy
Description: Pulse Radio Frequency mode is a high voltage and low temperature Radio Frequency mode formed by discontinuous and pulsed current around nerve tissue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham operation
Description: The means to achieve double-blind treatment had no practical effect on the subjects

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham operation
Description: The means to achieve double-blind treatment had no practical effect on the subjects
Study: NCT05944887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol injection
Description: Sedation by total intravenous administration (TIVA) of propofol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastroscopy
Description: esogastroduodenoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: gastroscopy
Description: esogastroduodenoscopy
Study: NCT06315348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flapless alveolar decortication with augmentation
Description: piezocision-assisted orthodontics, concomitant to soft tissue grafting (volume-stable collagen matrix), with piezocision-assisted orthodontics, concomitant to bone grafting with a xenograft and a native collagen membrane. Piezocisions will be performed using a piezoelectric device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: flapless alveolar decortication with augmentation
Description: piezocision-assisted orthodontics, concomitant to soft tissue grafting (volume-stable collagen matrix), with piezocision-assisted orthodontics, concomitant to bone grafting with a xenograft and a native collagen membrane. Piezocisions will be performed using a piezoelectric device.
Study: NCT06557044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: PENG block with ropivacaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: Placebo control
Study: NCT05069935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 is an allogeneic natural killer (NK)-cell immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 is an allogeneic natural killer (NK)-cell immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody - Dose Escalation
Description: either avelumab, trastuzumab or cetuximab

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody - Dose Expansion
Description: either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab
Study: NCT05621954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telehealth Monitoring
Description: Connected devices and smartphone apps to measure symptoms and observations at home, with centralisation of results to a staffed hub
Study: NCT06295094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 10.5 mg/m2 body surface in 150ml saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 2.1 mg/m2 body surface in 50ml saline
Study: NCT05543694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Subjects will receive a dose of bupivacaine as described in the arm section of this trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Subjects will receive a dose of bupivacaine as described in the arm section of this trial
Study: NCT05397795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10000 IU hCG (Choriomon5000 IU; IBSA)
Description: 10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10000 IU hCG (Choriomon5000 IU; IBSA)
Description: 10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring)
Description: GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.
Study: NCT04980248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1850
Description: ALXN1850 will be administered as an IV infusion and via the SC route.
Study: NCT05701111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start with the Heart Students
Description: The Start with the Heart curriculum includes psychoeducation, lessons, and activities, on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition to promote well-being. The curriculum will be taught in the classroom to students for 15-20 min per day for 6-8 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Start with the Heart Students
Description: The Start with the Heart curriculum includes psychoeducation, lessons, and activities, on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition to promote well-being. The curriculum will be taught in the classroom to students for 15-20 min per day for 6-8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start with the Heart Teachers
Description: Pure Edge Inc will train teachers to deliver the Start with the Heart curriculum. The training emphasizes the neuroscience of stress and educator self-care. The teachers will implement the training in their respective classrooms for 6-8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Centered Therapy Counselors
Description: The Early Life Stress and Resilience Program team members will train school counselors on Cue-Centered Therapy through self-paced online modules, virtual and in-person live training, and office hours as needed. Counselors will implement the intervention with eligible students for 15-18 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Centered Therapy Students
Description: Students who report a threshold of PTSD symptoms will be offered participation in Cue-Centered Therapy with their school counselors. They will have one-on-one therapy that targets trauma experiences through cognitive behavioral tools, narrative therapy, exposure therapy, psychoeducation, and more. Their caregivers will be involved as needed. They will enroll in treatment for 15-18 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cue Centered Therapy Students
Description: Students who report a threshold of PTSD symptoms will be offered participation in Cue-Centered Therapy with their school counselors. They will have one-on-one therapy that targets trauma experiences through cognitive behavioral tools, narrative therapy, exposure therapy, psychoeducation, and more. Their caregivers will be involved as needed. They will enroll in treatment for 15-18 weeks.

Intervention type: GENETIC
Group type: OTHER
Intervention: iSWAB-DNA
Description: Eligible students will give DNA buccal swabs at 2-3 time points for later analysis of genetic markers.
Study: NCT06144528

Intervention type: OTHER
Intervention: QT robot
Description: In a single session each child will be video-recorded while performing the task. The participant subjects will perform the same task at two different times, once with the human operator and once with the Qt robot. Both tasks will have a duration of approximately 4 minutes. During the first minute, both the operator and the Qt will introduce themselves and ask four questions to the child to deepen the acquaintance. In the second minute, the operator/Qt will tell a story. In the third minute, the operator/Qt will ask to imitate 4 motor movements, while in the fourth minute, the operator/Qt will ask to imitate 4 facial expressions.
Study: NCT05745896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine appointment
Description: Three online appointments for pregnancy monitoring at prenatal care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face appointment
Description: Six to nine face-to-face appointments for pregnancy monitoring at prenatal care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face appointment
Description: Six to nine face-to-face appointments for pregnancy monitoring at prenatal care.
Study: NCT05129813

Intervention type: BEHAVIORAL
Intervention: Recovery Guide Counseling
Description: Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling

Intervention type: BEHAVIORAL
Intervention: Recovery Guide Counseling
Description: Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling
Study: NCT05186779

Intervention type: DRUG
Intervention: Progestagen
Description: Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer

Intervention type: DRUG
Intervention: Progestagen
Description: Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer
Study: NCT05265299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81mg
Description: Aspirin 81mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81mg
Description: Aspirin 81mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81mg
Description: Aspirin 81mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81mg
Description: Aspirin 81mg once daily
Study: NCT05518487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
Description: 0.5 mL per dose of the Sanofi-GSK COVID-19 Vaccine will be administered intramuscularly in the deltoid muscle of the upper arm
Study: NCT05265299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81mg
Description: Aspirin 81mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81mg
Description: Aspirin 81mg once daily
Study: NCT05432973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrical Nerve Stimulation
Description: In the PENS treatment, a biphasic continuous waveform current with a frequency of 2 Hz, a pulse width of 50 microseconds and an intensity that produces visible motor responses of the innervated muscles was used, below the patient's pain threshold. The NT6021 Percutaneous Neuromodulation equipment of the Nutek® brand distributed by Fisiolab Ibérica® was used. This equipment has the CE marking, which denotes compliance with the requirements of the legislation of Royal Decree 414/1996 of March 1, which regulates medical devices. B.O.E. of April 24, 1996

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurodynamic and manual therapy
Description: The manual therapy consisted of passive-assisted mobilization and massage therapy of the muscular and fascial tissue, beginning with the cervical area, kneading while asking the patient to rotate the neck and then in the same way along the muscles and soft tissues innervated by the target nerve.~Neurodynamic was performed in a passive-assisted manner, combining the patient's cervical mobilizations with the mobility of the upper limbs adapted to each case.
Study: NCT05265299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg
Description: Aspirin 162 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg
Description: Aspirin 162 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg
Description: Aspirin 162 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg
Description: Aspirin 162 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg
Description: Aspirin 162 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg
Description: Aspirin 162 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Aspirin 325mg once daily
Study: NCT05460806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants assigned to aerobic exercise training will walk on a treadmill (RodbyTM, RL 1600E, Enhorna, Sweden) for 40 minutes at an intensity of 60-75% of maximum heart rate (220-age formula) three times per week for 8 weeks. The heart rate of the participants will be measured with an electric heart rate monitor throughout the session.
Study: NCT04312191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mantra Meditation
Description: Mantra-based meditation will be taught using a standard one-word mantra (Om). Om is a non-English word that will help with focus as opposed to an English word which may cause distraction based on the word itself.
Study: NCT06213051

Intervention type: DEVICE
Intervention: • COPAN Self-collection FLOQSwabs® (COPAN, Italy)
Description: COPAN swabs evaluated on Roche COBAS and Cepheid Xpert PCRs
Study: NCT05265299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Aspirin 325mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Aspirin 325mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Aspirin 325mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Aspirin 325mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Aspirin 325mg once daily
Study: NCT06015113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin plus pyrotinib or naratinib
Description: Trastuzumab Injection: Intravenous infusion, initial loading dose of 2 mg/kg, administered via intravenous infusion over 30-90 minutes (usually recommended around 60 minutes), administered on day 1 of each cycle, with each cycle lasting 14 days.~Pyrotinib Maleate Tablets: 400 mg, taken orally once daily, within 30 minutes after a meal, at the same time every day. Taken continuously, with each cycle lasting 14 days.~Neratinib Maleate Tablets: 240 mg, taken orally once daily with a meal, at the same time every day. The neratinib tablet should be swallowed whole (it should not be chewed, crushed, or split before swallowing). Taken continuously, with each cycle lasting 14 days.